Drug Delivery Devices - China

China

Highlights

In China, revenue in the Drug Delivery Devices market market is projected to reach US$3.25bn in 2024.
This revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 6.56%, leading to a market volume of US$4.46bn by 2029.
In a global context, the majority of revenue will be generated the United States, which is estimated to reach US$15.01bn in 2024.
In China, the rapid advancement of digital healthcare technologies is significantly driving innovation and adoption in drug delivery devices within the medical technology sector.

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Drug Delivery Devices Market within the Medical Devices sector in China is witnessing moderate growth, influenced by factors such as technological advancements, increasing patient demand for personalized medicine, and a rising focus on chronic disease management solutions.

Customer preferences: In China, there is a growing preference for user-friendly drug delivery devices that cater to the lifestyle needs of diverse demographics, particularly the aging population and urban dwellers. Patients increasingly favor devices that offer convenience, such as pre-filled syringes and smart inhalers, which enhance adherence to medication regimes. Additionally, the rise of health awareness among younger consumers is driving demand for personalized drug delivery solutions that align with their proactive approach to health management and chronic disease prevention.

Trends in the market: In China, the Drug Delivery Devices Market is experiencing a significant shift towards innovative and user-centric solutions, reflecting the evolving needs of its diverse population. The demand for pre-filled syringes and smart inhalers is increasing, driven by the desire for convenience and improved medication adherence among patients, particularly the elderly and urban residents. Furthermore, younger consumers are advocating for personalized drug delivery options that align with their health management goals, fostering a proactive approach to chronic disease prevention. This trend highlights the importance of adaptability for industry stakeholders, as they must prioritize user-friendly designs and smart technologies to capture market share and enhance patient outcomes.

Local special circumstances: In China, the Drug Delivery Devices Market is shaped by a rapidly aging population and urbanization, creating distinct healthcare demands. The emphasis on traditional Chinese medicine influences the acceptance of innovative drug delivery methods, merging Western technology with local practices. Additionally, stringent regulatory frameworks ensure safety and efficacy, fostering trust in new devices. Cultural attitudes towards health management are evolving, with an increasing preference for preventative care solutions, driving the need for customized drug delivery systems that cater to individual health goals and lifestyles.

Underlying macroeconomic factors: The Drug Delivery Devices Market in China is significantly influenced by macroeconomic factors such as the country’s economic growth, healthcare expenditure, and evolving regulatory landscapes. As China’s economy continues to expand, increased investment in healthcare infrastructure bolsters the development of innovative drug delivery solutions. Additionally, supportive government policies aimed at enhancing healthcare access and quality drive demand for advanced medical devices. The rise in chronic diseases and a growing emphasis on personalized medicine further propel the market, as patients seek tailored delivery systems that align with their health management needs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Explore more high-quality data on related topic

Medical technology industry - statistics & facts

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.